BELGRADE, Serbia, Nov. 18 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com Slavica Bio Chem operating subsidiary www.slavicabiochem.com is pleased to report that IBISS research group passed to the top final for biological science out of more than hundred competitors in the contest for the annual Award "Best technological innovation in Serbia in the year 2009" announced by Serbian Ministry of Science and Technological Development (MSTD).
Prof. Dr. Mirjana Stojiljkovic, a Medical Advisor of HTDS, the project and team leader of the IBISS group, said: "We are proud our idea and the marketing plan were well accepted and we hope that we shall be as successful as our colleagues from MindUp group. Namely, in the competition for the Best Technological Innovation in Serbia in the year 2008, Ministry of Science and Technological Development (MSTD) of Republic of Serbia awarded MindUp cancer project the second place in the field of biology for the establishment of the resistant human lung cancer cell line, and their contribution to overcome of multi-drug resistance, a major obstacle in the failure of standard chemotherapy". At the company website http://www.htdsmedical.com/awards.html and on http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds one can find the Certificate of this prestigious award, which was presented to the MindUp project leaders (the project was listed as 143009 in the MSTD).
Prof. Dr. Mirjana Stojiljkovic added: "Decision of the Award Committee for 2009 is expected shortly and we are hoping for the best." Additional details and information will be released promptly, via regular news release or Pink Sheets filing service.
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
SOURCE Hard to Treat Diseases